Do you offer alectinib as first-line therapy for ALK-positive metastatic NSCLC?
Since results of the phase III J-ALEX study were reported at ASCO 2016, do you try to obtain alectinib in the first-line setting instead of crizotinib?
Answer from: Medical Oncologist at Academic Institution
For a patient with multiple (>10) asymptomatic brain metastases as well as systemic metastatic disease, you could make a strong argument for starting with first line alectinib. It would require some work as it is not currently approved for first line. For patients without brain metast...
Sign in or Register to read more